



Memorandum

To: Gold Coast Health Plan Practitioners

From: Dr. Nancy Wharfield, Associate Chief Medical Officer

Re: **Respiratory syncytial virus (RSV) and the use of Palivizumab (Synagis®)**

Date: November 4, 2015

Gold Coast Health Plan (GCHP) cares about the health of its members. RSV is the leading cause of lower respiratory tract infections in infants and young children. GCHP has adopted the American Academy of Pediatrics (AAP) recommendations for RSV immunoprophylaxis to establish clinical criteria for RSV season, which began Nov. 1 and ends March 31.

There are certain factors that make Palivizumab (Synagis®) eligible for approval by California Children's Services (CCS).

To learn more about RSV and how infants can qualify for Palivizumab (Synagis®)
[Click here](#)

GCHP has identified the Synagis® Clinic at the Ventura County Medical Center (VCMC) Pediatric Diagnostic Center as the preferred provider for Synagis® administration to its Members.

Requests for Synagis® can be submitted directly to the VCMC Pediatric Diagnostic Center for initial screening to determine if the request meets medical necessity criteria or CCS eligibility. Please include with the request the NICU discharge summary and any other supportive clinical documentation to expedite the review process.

To access the Synagis® request form
[Click here](#)

Fax completed forms to:

VCMC Pediatric Diagnostic Center, Attention: Kay, Fax: 1-805-652-3375